NYSE:CSU

Delisted

Capital Senior Living Stock News

Healthcare > Medical - Care Facilities

Buy CSU

*Your capital is at risk

$33.30

+0 (+0%)

At Close: Jul 20, 2022

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

02:45pm, Friday, 27'th Feb 2026

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved qu

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

07:00am, Friday, 27'th Feb 2026

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

06:29am, Friday, 27'th Feb 2026

Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

01:15am, Monday, 23'rd Feb 2026

Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spon

Constellation Software Inc. Announces Conference Call to Discuss Fourth Quarter Results

05:51pm, Tuesday, 17'th Feb 2026

TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it will host a fourth quarter conference call and live audio webcast on March 10, 2026 at 8:00 a.m. ET

Constellation Software (TSE:CSU) Reaches New 52-Week Low – Time to Sell?

04:22am, Tuesday, 20'th Jan 2026

Constellation Software Inc. (TSE: CSU - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday. The company traded as low as C$2,791.01 and last traded at C$2,791.01, with

Constellation Software Inc. Announces Annual Interest Rate for Series 1 Debentures

05:07pm, Monday, 19'th Jan 2026

TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU, TSX: CSU.DB) (the “Company”) announced today that the interest rate applicable to the unsecured subordinated float

Barry Alan Symons Sells 2,500 Shares of Constellation Software (TSE:CSU) Stock

04:06am, Monday, 15'th Dec 2025

Constellation Software Inc. (TSE: CSU - Get Free Report) insider Barry Alan Symons sold 2,500 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

07:30am, Monday, 10'th Nov 2025

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern I

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

05:23pm, Tuesday, 30'th Sep 2025

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by